Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.
Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.
In the last two decades, antiretroviral therapy has dramatically improved the health of people living with HIV. Let’s take a brief look at the past and present before we look forward to HIV treatment in 2020.
In this interview, Joel E. Gallant, M.D., M.P.H., discusses new HIV drugs in the pipeline and the lack of young people becoming HIV care specialists.
Asier Sáez-Cirión, Ph.D., of the Institut Pasteur in Paris, sits down with IFARA to talk about his case study of a French teenager who has achieved HIV remission for 12 years.
A long-term aspirational goal is the elimination of HIV. In 1996, highly active antiretroviral therapy was thought to constitute a cure. Then latency was discovered to be a cure barrier. Today, achieving long-term remission of the virus is considered...
In these formative stages of HIV cure research, scientists have largely been focused on the challenges presented by the virus and the immune system, leaving considerations of diverse populations of HIV-positive people aside. That is beginning to chan...
While no one is calling this case a cure, it does raise some interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.